Home > Finance > UK's De La Rue in talks for potential stake sale
Finance

UK's De La Rue in talks for potential stake sale

Published by Global Banking and Finance Review

Posted on December 12, 2024

Featured image for article about Finance

(Reuters) - British banknote maker De La Rue on Thursday confirmed it was in talks with Disruptive Capital GP and Pension SuperFund Capital regarding a potential sale of up to 40% of its equity at a price of 1.25 pounds per share ($1.58 per share).

($1 = 0.7890 pounds)

(Reporting by Raechel Thankam Job; Editing by Anil D'Silva)

Related Posts
Oil prices jump on Trump's Venezuela blockade
Oil prices jump on Trump's Venezuela blockade
Dollar holds gains against sterling, yen as central bank decisions loom
Dollar holds gains against sterling, yen as central bank decisions loom
Tech jitters dent stocks before central banks take centre stage
Tech jitters dent stocks before central banks take centre stage
Rheinmetall to sell civil business, takes 350 million euro impairment
Rheinmetall to sell civil business, takes 350 million euro impairment
Bank of England set to cut rates as inflation and economy slow
Bank of England set to cut rates as inflation and economy slow
BP appoints Woodside's Meg O'Neill as CEO after Auchincloss' abrupt exit
BP appoints Woodside's Meg O'Neill as CEO after Auchincloss' abrupt exit
BP's chief executives since 1990
BP's chief executives since 1990
LVMH CEO Arnault: Ask me again in 10 years about succession plans 
LVMH CEO Arnault: Ask me again in 10 years about succession plans 
Trading Day: Tech slumps, oil spikes
Trading Day: Tech slumps, oil spikes
IMF says Moldova's economy has unique growth opportunity, but reforms needed
IMF says Moldova's economy has unique growth opportunity, but reforms needed
UK firm Awendio Solaris plans $725 million solar plant with indigenous groups in Canada
UK firm Awendio Solaris plans $725 million solar plant with indigenous groups in Canada
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie, several other pharma companies near MFN deal with Trump, sources say